Regular ArticleDifferential effects of the iodinated contrast agents Ioxaglate, Iohexol and Iodixanol on thrombus formation and fibrinolysis☆
Introduction
Since their introduction, iodinated, angiographic contrast agents have been widely used in interventional procedures for coronary artery disease. The early, high osmolar agents have, since the late 1970s, been largely superseded by low/iso osmolar contrast media (CM). There are currently four general classes of contrast agents, which can be ionic or non-ionic, and either monomeric or dimeric.
Low osmolar CM are generally found to be anticoagulant in vitro, with ionic CM having a greater anticoagulant effect than the non-ionic agents [1], [2], [3], [4], [5], [6]. Despite these anticoagulant effects in vitro, a body of evidence has accumulated that suggests that non-ionic CM are associated with increased thrombus formation in animal models [7], [8], [9], [10], [11], and thrombi have been reported in syringes containing non-ionic CM contaminated with blood [12]. This does not appear to be the case with the dimeric ionic CM, Ioxaglate, which has been shown to reduce thrombus occlusion in a canine arterial balloon injury model [8], reduce time to formation of occlusive thrombi at clinically relevant concentrations in a rat carotid artery injury model [13], reduce thrombus formation on catheters [14] and to inhibit platelet and fibrin deposition on stents in a baboon femoral shunt model [15]. Similarly, ionic CM inhibited platelet adhesion and aggregation more than non-ionic CM in a parallel plate flow model [16] and Ioxaglate has been shown to reduce platelet aggregation in response to collagen [17].
Part of the effects of the different CM on haemostasis may stem from their differential effects on platelets. Early reports suggested CM inhibited platelet aggregation [18]. However, more recently it has been recognized that low osmolar CM cause platelet degranulation, as evidenced by expression of α-granule membrane P-selectin (CD62P) and lysosomal membrane antigen CD63 (GP53), and by the release of platelet α-granule (βTg, PF4) and dense granule (5-HT) contents [19], [20], [21]. This effect does not equate to platelet activation as it is seen without the activation of platelet GPIIbIIIa [19]. Comparison of the different types of CM has demonstrated that degranulation is greater with non-ionic than with ionic CM, whilst the ionic dimer, Ioxaglate, causes little or no platelet degranulation or activation [19], [20], [21]. Ioxaglate also has a marked inhibitory effect on thrombin-induced platelet activation [19], [22], which appears to be mediated though a direct interaction with thombin [22] and is not seen when platelets are stimulated directly through the PAR-1 thrombin receptor [18], [21]. This is supported by recent studies which have demonstrated that Ioxaglate inhibits thrombin generation in platelet poor and platelet rich plasma through interference of the activation of FV and FVIII by thrombin [4], [23].
In addition, CM have an effect on fibrinolysis/thrombolysis. This may, in part, be a consequence of enhanced platelet degranulation, since platelet α-granules contain large amounts of PAI-1, FXIII, and TAFI which become incorporated into the growing thrombus, and are responsible for resistance to fibrinolytic agents. As well as this CM have a negative effect on fibrinolysis, by giving rise, to thinner fibrin filaments, that are more resistant to fibrinolysis/thrombolysis [24], [25], [26], [27]. This has been reported both in vitro and in vivo [24], [25], [26], [27], [28], [29], and in those studies where comparisons have been made between contrast agents, the ionic dimer Ioxaglate has less antifibrinolytic effect than non-ionic CM [29].
The literature on the effects of CM is contradictory and difficult to interpret due to the array of different CM used and because components of the haemostatic system have been investigated individually and out of context of changes in the rest of the system. Therefore there is a need for a more encompassing approach to understand the clinically relevant effect of CM on thrombus formation and fibrinolysis. Here we utilized a model to create whole blood thrombi in vitro under conditions of flow (Chandler loop [30]). Thrombi formed in this way have been shown to closely resemble arterial thrombi with a distinct platelet rich head and fibrin tail [31]. Adding CM to the blood prior to thrombus formation gives a physiologically relevant model to evaluate the effects of CM on thrombus formation and fibrinolysis.
In this study, we set out to compare the effect of three different classes of contrast agents non-ionic monomer Iohexol (Omnipaque), non-ionic dimer Iodixanol (Visipaque), and ionic dimer Ioxaglate (Hexabrix) on thrombus formation, fibrinolysis and tPA mediated thrombolysis, and to evaluate the role of platelets in this process.
Section snippets
Materials and blood samples
The following CM were investigated: the Non-ionic monomer Iohexol (Omnipaque, Amersham-Health) osmolality 850 mosMol/kg; the Non-ionic dimer Iodixanol (Visipaque, Nycomed-Amersham) osmolality 290 mosMol/kg; the Ionic dimer Ioxaglate (Hexabrix, Guerbet) osmolality 600 mosMol/kg.
Blood was taken from eight normal, healthy volunteers using a standardized phlebotomy technique to minimize the activation of platelets. Blood was taken into plain vacutainer tubes (BD Vacutainer Systems, Oxford, UK),
Thrombus formation in the presence of CM
The effects of the CM on thrombus formation were markedly different (Fig. 1). Control thrombi formed in 20% (v/v) saline weighed 11±2 mg. With Ioxaglate, no thrombi formed in blood either in the presence of 50% or 20% (v/v) CM. Thrombi formed from blood mixed 20% (v/v) with Iohexol or Iodixanol weighed significantly more (≥10×) than control thrombi formed with 20% (v/v) saline (116±52 and 230±128 mg vs. 11±3 mg, respectively; p<0.0005). Thrombi formed with 20% (v/v) Iodixanol weighed
Discussion
In this study, we have shown that the non-ionic monomer Iohexol and the non-ionic dimer Iodixanol increased both thrombus formation and the resistance to fibrinolysis within thrombi, whilst the ionic dimer Ioxaglate inhibits thrombus formation. These results are entirely consistent with previous findings of thrombus formation in vivo with non-ionic but not ionic CM, and with in vitro studies showing increased fibrinolytic resistance with Iohexol but not Ioxaglate, increased platelet
Acknowledgements
This work was supported by Guerbet, Aulney Sous Bois, France.
References (32)
- et al.
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis?
Thromb. Res.
(2002) - et al.
Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility
Clin. Mater.
(1991) - et al.
The ionic contrast medium Ioxaglate interferes with thrombin-mediated activation of factor V, factor VIII and platelets
J. Thromb. Haemost.
(2003) - et al.
Fibrin modification by ionic and non-ionic contrast media during cardiac catheterisation
Am. J. Cardiol.
(1992) - et al.
Alterations in fibrin detected in coronary sinus blood after heparin and coronary angiography with a non-ionic contrast agent (Iohexol)
Am. J. Cardiol.
(1998) - et al.
Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents
JACC
(1995) - et al.
Effect of iodinated contrast media on blood clotting
Invest. Radiol.
(1989) - et al.
Thrombin generation in non-clottable mixtures of blood and non-ionic contrast agents
Radiology
(1990) - et al.
In vitro comparison of the effects of contrast media on coagulation and platelet activation
Blood Coagul. Fibrinolysis
(1996) - et al.
Anticoagulant and antiplatelet effect of an ionic iodinated contrast medium, but not of a non-ionic one
Am. J. Cardiol.
(2000)
Thrombotic risk associated with the use of iodinated contrast media in interventional cardiology: pathophysiology and clinical aspects
Fundam. Clin. Pharmacol.
Effect of an ionic compared to a non-ionic X-ray contrast agent on platelets and coagulation during diagnostic cardiac catheterization
Pathophysiol. Haemost. Thromb.
Variable effects of radiological contrast media on thrombus growth in a rabbit jugular vein thrombosis model
Thromb. Haemost.
Acute thrombosis in a canine model of arterial injury: effect of ionic versus non-ionic contrast media
J. Invas.Cardiol.
Comparative procoagulant actions of ionic and non-ionic contrast media as studied in a rat model of laser induced thrombosis
Thromb. Haemost.
Effect of iodinated contrast agents on the formation of platelet thrombi in the micro arterioles of rats
Invest. Radiol.
Cited by (37)
Stability of erythrocyte membrane and overall hemostasis potential - A biocompatibility study of mebrofenin and other iminodiacetic acid derivatives
2015, Pharmacological ReportsCitation Excerpt :These authors found that the clot formed in presence of iohexol is characterized by altered fibrin structure, making it less responsive to fibrinolytic agents [33]. Furthermore, another in vitro study showed that the clots formed in presence of iodixanol and iohexol are larger and more resistant to thrombolysis than those formed in presence of ioxaglate [34]. We assume that the changes observed during the clot stabilization phase might reflect an increase in the activity of factor XIII, which was stimulated by the addition of the tested ligands.
Contrast-induced thrombosis: Are we aware?
2015, Journal of Vascular and Interventional RadiologyEffect of iodinated low-osmolar contrast media on the hemostatic system after intraarterial and intravenous contrast administration
2012, Advances in Medical SciencesCitation Excerpt :Hemostatic activation plays a significant role in pathophysiology of many vascular diseases (i.a. ischaemic heart disease) and may be a result of low-invasive treatment methods (vessel catheterisation, stenting, embolisation). Thus, the effects of contrast agents on hemostatic mechanisms may be clinically significant for the choice of the right imaging method and contrast agent, to prevent complications [2,6,7]. The aim of this work was to assess the influence of iodinated contrast agents on the activity of the hemostatic system.
The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo
2008, Journal of Vascular SurgeryCitation Excerpt :Blood was collected from the arterial catheter into Vacutainer tubes (BD UK Ltd, Oxford, UK) containing either CTAD (citrate, theophylline, adenosine and dipyridamole), or tris-sodium citrate (0.105M; BD). Thrombi were generated from whole blood in a Chandler loop, using a method previously described.22-24 Aliquots of 0.9 mL of citrated blood were supplemented with 50 μL of 1 mg/mL fluorescein isothiocyanate (FITC)-fibrinogen (prepared in house24), recalcified, and placed into polythene tubing 45-cm long.
- ☆
Presentation: this work was presented at the ISTH 2003 conference.